Tuochuang biology obtained more than 200 million yuan of round B financing to accelerate the development and clinical promotion of innovative antibody drugs

Yiouda health learned on the 19th that recently, Tuochuang Biotechnology (Suzhou) Co., Ltd. (hereinafter referred to as "Tuochuang biology") announced that it had completed a round B financing of more than 200 million yuan. This round of financing is led by CIC and jointly invested by FengChuan capital. In the first half of 2021, the company has just completed tens of millions of dollars of a + round financing. It is reported that the raised funds will be used for the promotion of clinical trials of the company's pipeline under research and early R & D and preclinical research of other projects. Tuochuang biology is a multifunctional specific antibody drug company with the world's cutting-edge protein engineering technology. It focuses on the field of tumor and self immune diseases, and is committed to challenging the research and development of non patent drugs and other innovative target drugs. At present, it has established three innovative breakthrough technology platforms, namely: the independently developed phage biolibrary tavoselect, the protein engineering platform tavoprecision supporting the research and development of double antibody and multi antibody, and the polycyclic peptide platform tavomip focusing on overcoming non drug targets. Based on these platforms, Tuochuang biology has nearly ten pipelines under research. Among them, two varieties will apply for us ind by the end of 2021, and will move forward at the rate of applying for ind of at least two varieties every year in the future.